Innovative polyethylene film sets new benchmark
Sartorius Stedim Biotech is introducing a new scalable range of single-use bags, Flexsafe, for the implementation of single-use bioprocessing at all stages of drug manufacture, from process development to production both upstream and downstream. The innovative concept of Flexsafe addresses key industry requirements for future-proof single-use manufacturing of commercial vaccines and drugs.
Developed in close collaboration with resin and film suppliers, Flexsafe is based on a multilayer, proprietary polyethylene (PE) film, S80. A standardized cell growth assay has been used to optimize film formulation, determine the operating ranges for extrusion, welding and gamma-irradiation processes and to establish specifications and process controls.
Flexsafe ensures excellent and reproducible cell growth behavior of the most sensitive cell lines. The optimization of the resin formulation, the complete control of raw materials, the extrusion process and the bag assembly guarantee lot-to-lot consistent cell growth performance.
Flexsafe offers strength and flexibility with its robust 400 μm thick PE film. The bags enable safe and easy-to-use operation, including applications such as liquid shipping and large-scale stirred bioreactors.
Consistent batch-to-batch extractables and leachables profiles support drug manufacturers throughout the entire lifecycle of modern biological treatments from clinical development to commercial supply many years after launch. Users have the assurance that the initial extractable and leachable qualification work and data remain valid every time they operate their single-use Flexsafe bioprocess.
Assurance of supply is also guaranteed as a result of long-term contracts with suppliers and business continuity plans with defined safety stocks and global manufacturing capabilities including resin manufacturing.
Sartorius Stedim Biotech is launching Flexsafe RM bags (1L-200L) and small bags for validation purposes first. Bags for single use bioreactors BIOSTAT STR (50-2000L) and additional applications such as storage, mixing, shipping freeze and thaw will be rolled out step by step.
Source: Sartorius
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.